Back

Sonnet BioTherapeutics Delays Merger Vote for $888M Hyperliquid Strategies Deal

HyperLiquid Strategies’ Nasdaq debut is pushed back due to incomplete shareholder voting, with completion expected in at least two weeks.

HYPE

Summary

Sonnet BioTherapeutics announced a delay in finalizing its $888 million merger with Rorschach I LLC to create Hyperliquid Strategies, citing incomplete shareholder voting. The postponement of the deal will extend the process by at least two more weeks before the digital asset treasury firm’s Nasdaq listing. The planned company is set to hold 12.6 million HYPE tokens and $305 million in cash, backed by major investors including Paradigm and Galaxy Digital.

Terms & Concepts
  • HYPE tokens: A cryptocurrency associated with Hyperliquid Strategies, likely representing utility or governance rights within its ecosystem.
  • Nasdaq listing: A public offering of company shares on the Nasdaq Stock Market, one of the world’s largest securities exchanges.
  • Paradigm: A major cryptocurrency investment firm known for backing blockchain and digital asset projects.